Brain Advance Access published online on November 29, 2005
Brain, doi:10.1093/brain/awh682
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Epileptology, University of Bonn Medical Center, Bonn, Germany
* To whom correspondence should be addressed. Epilepsy is a common and devastating neurological disorder. In many patients with epilepsy, seizures are well-controlled with currently available anti-epileptic drugs (AEDs), but a substantial (
Received April 13, 2005
Revised July 22, 2005
Accepted October 13, 2005
Review Article
Molecular and cellular mechanisms of pharmacoresistance in epilepsy
Stefan Remy 1
and
Heinz Beck 1 *
Heinz Beck, E-mail: heinz.beck{at}ukb.uni-bonn.de
![]()
Abstract
30%) proportion of patients continue to have seizures despite carefully optimized drug treatment. Two concepts have been put forward to explain the development of pharmacoresistance. The transporter hypothesis contends that the expression or function of multidrug transporters in the brain is augmented, leading to impaired access of AEDs to CNS targets. The target hypothesis holds that epilepsy-related changes in the properties of the drug targets themselves may result in reduced drug sensitivity. Recent studies have started to dissect the molecular underpinnings of both transporter- and target-mediated mechanisms of pharmacoresistance in human and experimental epilepsy. An emerging understanding of these underlying molecular and cellular mechanisms is likely to provide important impetus for the development of new pharmacological treatment strategies.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. A. Dichter Emerging Concepts in the Pathogenesis of Epilepsy and Epileptogenesis Arch Neurol, April 1, 2009; 66(4): 443 - 447. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Jones, E. C. Merrick, T. W. Batts, N. J. Hargus, Y. Wang, J. P. Stables, E. H. Bertram, M. L. Brown, and M. K. Patel Modulation of Sodium Channel Inactivation Gating by a Novel Lactam: Implications for Seizure Suppression in Chronic Limbic Epilepsy J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 201 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Epsztein, Y. Ben-Ari, A. Represa, and V. Crepel Late-Onset Epileptogenesis and Seizure Genesis: Lessons From Models of Cerebral Ischemia Neuroscientist, February 1, 2008; 14(1): 78 - 90. [Abstract] [PDF] |
||||
![]() |
M. Weiergraber, M. Henry, K. Radhakrishnan, J. Hescheler, and T. Schneider Hippocampal Seizure Resistance and Reduced Neuronal Excitotoxicity in Mice Lacking the Cav2.3 E/R-Type Voltage-Gated Calcium Channel J Neurophysiol, May 1, 2007; 97(5): 3660 - 3669. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jandova, D. Pasler, L. L. Antonio, C. Raue, S. Ji, M. Njunting, O. Kann, R. Kovacs, H.-J. Meencke, E. A. Cavalheiro, et al. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices Brain, December 1, 2006; 129(12): 3290 - 3306. [Abstract] [Full Text] [PDF] |
||||




